Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study.
Level 2 - randomized trial
Post hoc subgroup analysis of an individual randomized controlled trial
PubMed 30958356 · doi:10.3233/JAD-181148
What was done
This post hoc analysis of the randomized, placebo-controlled OmegAD trial evaluated 171 community-based patients with mild to moderate Alzheimer's disease (MMSE ≥ 15). Patients received either daily omega-3 fatty acids (1.7 g DHA and 0.6 g EPA; n = 88) or placebo for 6 months. Investigators examined whether baseline plasma total homocysteine (tHcy), a marker of B vitamin status, modified the effect of omega-3 supplementation on cognitive and clinical measures (MMSE, global CDR, CDRsob, and ADAS-cog) using a general linear model and ANCOVA.
What was found
Baseline tHcy significantly interacted with omega-3 supplementation on MMSE (p = 0.040) and CDRsob (p = 0.023), with a trend on global CDR (p = 0.059), but no interaction on ADAS-cog (p = 0.649). Among patients with tHcy < 11.7 µmol/L, omega-3 supplementation improved MMSE by +7.1% (95% CI: 0.59% to 13.7%, p = 0.033) and improved CDRsob by -22.3% (95% CI: -5.8% to -38.7%, p = 0.009) compared with placebo.
Why it matters
These results suggest that adequate B vitamin status (reflected by lower homocysteine) is necessary to achieve cognitive benefits from omega-3 supplementation in Alzheimer's disease, potentially explaining past trial inconsistencies.
Limits
The study is a post hoc subgroup analysis, making findings exploratory rather than definitive. The intervention lasted only 6 months, and no significant interaction was observed for the standard ADAS-cog endpoint. Baseline B vitamin intake or serum concentrations were not directly reported in the abstract.
Cited by
- supports The OmegAD trial demonstrated that omega-3 supplementation did not result in cognitive benefit if participants had elevated homocysteine levels.